Engineering radiosensitizer‐based metal‐phenolic networks potentiate STING pathway activation for advanced radiotherapy

J Yan, G Wang, L Xie, H Tian, J Li, B Li… - Advanced …, 2022 - Wiley Online Library
Radiotherapy, a mainstay of first‐line cancer treatment, suffers from its high‐dose radiation‐
induced systemic toxicity and radioresistance caused by the immunosuppressive tumor …
被引用次数：127 相关文章

Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy

J Yan, G Wang, L Xie, H Tian, J Li… - Advanced …, 2022 - pubmed.ncbi.nlm.nih.gov
Radiotherapy, a mainstay of first-line cancer treatment, suffers from its high-dose radiation-
induced systemic toxicity and radioresistance caused by the immunosuppressive tumor …

Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy

J Yan, G Wang, L Xie, H Tian, J Li, B Li, W Sang, W Li… - 2022 - repository.um.edu.mo
Radiotherapy, a mainstay of first-line cancer treatment, suffers from its high-dose radiation-
induced systemic toxicity and radioresistance caused by the immunosuppressive tumor …

Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy.

J Yan, G Wang, L Xie, H Tian, J Li, B Li… - … (Deerfield Beach, Fla …, 2022 - europepmc.org
Radiotherapy, a mainstay of first-line cancer treatment, suffers from its high-dose radiation-
induced systemic toxicity and radioresistance caused by the immunosuppressive tumor …

Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy

J Yan, G Wang, L Xie, H Tian, J Li, B Li… - Advanced …, 2022 - ui.adsabs.harvard.edu
Radiotherapy, a mainstay of first-line cancer treatment, suffers from its high-dose radiation-
induced systemic toxicity and radioresistance caused by the immunosuppressive tumor …